PRODUCT MONOGRAPH

GLUMETZA®

Metformin Hydrochloride Extended-Release Tablets, Mfr. Std.
500 mg and 1000 mg

GLUMETZA® (SB)

Metformin Hydrochloride Extended-Release Tablets, Mfr. Std.
1000 mg

Oral Antihyperglycemic Agent

Name: Valeant Canada LP
Address: 4787 Levy St., Montreal, QC, H4R 2P9
Control Number: 151399

Date of Revision: June 14, 2012
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION
  Summary Product Information ................................................................. 2
  Indications and Clinical Use ................................................................. 2
  Contraindications .............................................................................. 3
  Warnings and Precautions ................................................................. 5
  Adverse Reactions ............................................................................ 9
  Drug Interactions ............................................................................. 12
  Dosage and Administration .............................................................. 14
  Overdosage ..................................................................................... 16
  Action and Clinical Pharmacology .................................................. 17
  Storage and Stability ....................................................................... 20
  Special Handling Instructions ......................................................... N/A
  Dosage Forms, Composition and Packaging ................................... 20

PART II: SCIENTIFIC INFORMATION
  Pharmaceutical Information ............................................................... 21
  Clinical Trials .................................................................................. 22
  Detailed Pharmacology .................................................................. 24
  Microbiology .................................................................................. N/A
  Toxicology ...................................................................................... 26
  References ...................................................................................... 28

PART III: CONSUMER INFORMATION .................................................. 30
PART 1: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Table 1: Summary Product Information

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form/Strength</th>
<th>Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>GLUMETZA Extended-release Tablets: 500 mg</td>
<td>hypromellose, microcrystalline cellulose, magnesium stearate, polyethylene glycol, polysorbate, titanium dioxide, polyethylene oxide.</td>
</tr>
<tr>
<td></td>
<td>GLUMETZA (SB) Extended-release Tablets: 1000 mg</td>
<td>colloidal silicon dioxide, crospovidone, dibutyl sebacate, ethylcellulose, glyceryl behenate, polyvinyl alcohol, povidone.</td>
</tr>
<tr>
<td></td>
<td>GLUMETZA Extended-release Tablets: 1000 mg</td>
<td>colloidal silicon dioxide, crospovidone, glyceryl behenate, polyvinyl alcohol, polyacrylate dispersion, hypromellose, talc, polyethylene glycol, titanium dioxide, simethicone emulsion, polysorbate, shellac glaze, iron oxide black, macrogol, n-butyl alcohol, propylene glycol, FD&amp;C blue #2, FD&amp;C yellow #6 and FD&amp;C red #40</td>
</tr>
</tbody>
</table>

For Complete Information see Dosage Forms, Composition and Packaging Sections

INDICATIONS AND CLINICAL USE

GLUMETZA and GLUMETZA (SB) (metformin hydrochloride) extended-release tablets are indicated for the control of hyperglycemia in adult patients with type 2 (non-insulin-dependent, mature onset) diabetes, as an adjunct to dietary management, exercise, and weight reduction, or when insulin therapy is not appropriate.

GLUMETZA and GLUMETZA (SB) may be used as monotherapy, or concomitantly with a sulfonylurea.
GLUMETZA and GLUMETZA (SB) are once-daily formulations, which must be taken with food to ensure optimum delivery of metformin to the systemic circulation. Clinical data demonstrates that administration of GLUMETZA and GLUMETZA (SB) in the fed state significantly increases the systemic delivery of metformin when compared to the fasted state. Metformin can be of value in the treatment of obese diabetic patients.

**Geriatrics**

Limited data from controlled pharmacokinetic studies of metformin hydrochloride in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged and $C_{\text{max}}$ is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function. Metformin treatment should not be initiated in patients greater than 80 years of age, unless measurement of creatinine clearance demonstrates that renal function is not significantly reduced. In patients with advanced age, metformin should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function (see **Warnings and Precautions**).

**Pediatrics**

The safety and efficacy of GLUMETZA and GLUMETZA (SB) in pediatric patients has not been established and no dosage regimen can be recommended in these patients.

**CONTRAINDICATIONS**

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the Product Monograph.

- Unstable and/or Type 1 (insulin-dependent) diabetes mellitus.

- Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma; history of ketoacidosis with or without coma. Diabetic ketoacidosis should be treated with insulin.

- In patients with a history of lactic acidosis, irrespective of precipitating factors.

- In the presence of renal impairment or when renal function is not known, and also in patients with serum creatinine levels above the upper limit of normal range. Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels $\geq 136 \mu\text{mol/L}$ (males), $\geq 124 \mu\text{mol/L}$ (females) or abnormal creatinine clearance) which may result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see also **Warnings and Precautions**).

- In excessive alcohol intake, acute or chronic.
In patients suffering from severe hepatic dysfunction. Since severe hepatic dysfunction has been associated with some cases of lactic acidosis, metformin hydrochloride should generally be avoided in patients with clinical or laboratory evidence of hepatic disease.

Metformin should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function (see Warnings and Precautions).

In cases of cardiovascular collapse and in disease states associated with hypoxemia such as cardiorespiratory insufficiency, which are often associated with hyperlactacidemia.

During stressful conditions, such as severe infections, trauma or surgery and the recovery phase thereafter.

In patients suffering from severe dehydration.

During pregnancy.
WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

- Lactic acidosis is a rare, but serious, metabolic complication that may occur during treatment with GLUMETZA and GLUMETZA (SB) (see Endocrine and Metabolism, Lactic Acidosis section below).

- Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking GLUMETZA and GLUMETZA (SB), since alcohol intake potentiates the effect of metformin on lactate metabolism (see Endocrine and Metabolism, Lactic Acidosis section below).

General
Use of GLUMETZA and GLUMETZA (SB) must be considered as treatment in addition to proper dietary and exercise regimen, and not as a substitute for either. Care should be taken to ensure that GLUMETZA and GLUMETZA (SB) are not given when a contraindication exists. If during metformin therapy the patient develops acute intercurrent disease such as clinically significant hepatic dysfunction, cardiovascular collapse, congestive heart failure, acute myocardial infarction, or other conditions complicated by hypoxemia which may also cause prerenal azotemia, the drug should be discontinued.

Endocrine and Metabolism

Lactic Acidosis:
Lactic Acidosis is a rare, but serious, metabolic complication that may occur during treatment with GLUMETZA and GLUMETZA (SB). When it occurs, it is fatal in approximately 50% of cases. Lactic acidosis may also occur in association with a number of pathophysiologic conditions, including diabetes mellitus, and whenever there is significant tissue hypoperfusion and hypoxemia. Lactic Acidosis is characterized by elevated blood lactate levels, decreased blood pH, electrolyte disturbances with an increased anion gap, and an increased lactate/pyruvate ratio. When metformin has been implicated in lactic acidosis, metformin plasma levels > 5ug/mL have been generally found.

The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is very low (0.03 cases/1000 patient years) with approximately half of those cases being fatal. Reported cases have occurred primarily in diabetic patients with significant renal insufficiency, including both intrinsic renal disease and renal hypoperfusion. Patients with congestive heart failure requiring pharmacologic management are at increased risk of lactic acidosis. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. The risk of lactic acidosis increases with the degree of renal dysfunction and the patient’s age. The risk of lactic acidosis may therefore, be significantly decreased by regular monitoring of renal function.
in patients taking GLUMETZA and GLUMETZA (SB), and by use of the minimum effective
dose of GLUMETZA and GLUMETZA (SB). In addition, GLUMETZA and GLUMETZA (SB)
should be promptly withheld in the presence of any condition associated with hypoxemia,
dehydration or sepsis. Because impaired hepatic function may significantly limit the ability to
clear lactate, GLUMETZA and GLUMETZA (SB) should generally be avoided in patients with
clinical or laboratory evidence of hepatic disease. Patients should be cautioned against excessive
alcohol intake when taking GLUMETZA and GLUMETZA (SB), since alcohol intake
potentiates the effect of metformin hydrochloride on lactate metabolism. The onset of lactic
acidosis often is subtle, and accompanied only by non-specific symptoms such as malaise,
myalgias, respiratory distress, increasing somnolence and non-specific abdominal distress. Lactic
acidosis is a medical emergency that must be treated in a hospital setting. In a patient with lactic
acidosis who is taking GLUMETZA and GLUMETZA (SB), the drug should be discontinued
immediately. Because metformin hydrochloride is dialysable, prompt hemodialysis is
recommended to correct the acidosis and remove the accumulated metformin.

**Hepatic/Biliary/Pancreatic**
Since impaired hepatic function has been associated with some cases of lactic acidosis,
GLUMETZA and GLUMETZA (SB) should generally be avoided in patients with clinical or
laboratory evidence of hepatic disease.

**Peri-operative Considerations**
Metformin therapy should be temporarily suspended for any surgical procedure (except minor
procedures not associated with restricted intake of food and fluids). Metformin should be
discontinued 2 days before surgical intervention and should not be restarted until the patient’s
oral intake has resumed and renal function has been evaluated as normal.

**Renal**
Metformin hydrochloride is excreted by the kidney, and the risk of metformin accumulation and
lactic acidosis increases with the degree of impairment of renal function. Patients with serum
creatinine levels above the upper limit of normal for their age should not receive metformin. In
patients with advanced age, metformin should be carefully titrated to establish the minimum dose
for adequate glycemic effect, because aging is associated with reduced renal function. In elderly
patients, renal function should be monitored regularly and generally should not be titrated to the
maximum dose. Before initiation of metformin therapy and at least annually thereafter, renal
function should be assessed and verified as normal. In patients in whom development of renal
dysfunction is anticipated, renal function should be assessed more frequently and GLUMETZA
and GLUMETZA (SB) discontinued if evidence of renal impairment is present (see Boxed
Warning on Lactic Acidosis).

Radiologic studies involving the use of iodinated contrast materials can lead to acute renal
failure, and have been associated with lactic acidosis in patients receiving metformin. Metformin
should be discontinued 2 days before radiologic studies and should not be restarted until the
patient’s oral intake has resumed and renal function has been evaluated as normal.
Sexual Function/Reproduction
There are no adequate and well-controlled studies in pregnant women. Reproduction studies have been conducted in rats at doses up to and including 900 mg/kg/day (approximately 33-fold and 26-fold higher than humans), and have revealed no evidence of harm to the fetus due to metformin. The NOAEL in rabbits was > 90 mg/kg/day, however, there were no toxicokinetic studies performed in rabbits and a relative exposure could not be determined. (See Part II, Scientific Information, Toxicology)

Carcinogenesis, Mutagenesis
A long-term carcinogenicity study was performed in rats (dosing duration of 104 weeks) at metformin doses up to and including 450 mg/kg/day for male rats and 1200 mg/kg/day for female rats. These doses are approximately two and five times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female rats. There was however, an increased incidence of adenomas and diffuse hyperplasia in the parathyroids of treated males. A carcinogenicity study was also performed in Tg.AC transgenic mice (dosing duration of 26 weeks) at doses up to 2000 mg/kg/day applied dermally. No evidence of carcinogenicity was observed in male or female mice. There was no evidence of mutagenic potential of metformin in the following in vitro tests: Ames test (S. typhimurium and E. coli), and gene mutation test (mouse lymphoma cells). Results of the in vivo mouse micronucleus test were also negative. Fertility of male and female rats was unaffected by metformin when administered at doses as high as 900 mg/kg/day, which is approximately four times the recommended human daily dose based on body surface area comparisons. (See Part II, Scientific Information, Toxicology)

Special Populations

Pregnant Women:
Safety of metformin in pregnant women has not been established. There are no adequate and well-controlled studies in pregnant women. Recent information strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities. Most experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

The GLUMETZA nonclinical toxicology program included a complete battery of reproductive toxicity studies (fertility and early embryonic development, embryofetal development, and pre- and postnatal development). The combined fertility and developmental toxicity study in rats, (0, 150, 450, or 900 mg/kg/day orally) showed no adverse effects on fertility or embryofetal development, although a decrease in male reproductive organ weights was observed at a dose of 900 mg/kg/day. An embryofetal development study in rabbits revealed no effects on gross external, soft tissue, or skeletal malformation or variations at dose up to 90 mg/kg/day. A perinatal/postnatal toxicity study in rats demonstrated few findings, except that there was an increased latency in the passive avoidance test for F1 males in the 300 and 600 mg/kg/day groups and a decrease in body weight and feed consumption for F1 females during the precohabitation period in the 300 and 600 mg/kg/day groups. Therefore, the viability and growth
NOAEL for this study was 150 mg/kg/day. Mating performance of F1 rats and caesarean-sectioning and litter parameters were unaffected at the highest dose of 600 mg/kg/day. Based on the results of these studies, it was concluded that metformin produced no biologically significant, reproductive toxicity effects.

**Nursing Women:**
It is not known whether metformin hydrochloride is excreted in human milk, however, studies in lactating rats have shown that metformin is excreted into milk and reaches levels comparable to those in plasma. Caution should be exercised in nursing mothers, and a decision should be made whether to discontinue nursing, or to discontinue treatment with GLUMETZA and GLUMETZA (SB), taking into account the importance of the drug to the mother.

**Pediatrics: (< 18 years of age)**
The safety and efficacy in pediatric patients have not been established and no dosage regimen can presently be recommended in these patients.

**Geriatrics: (> 80 years of age)**
Metformin treatment should not be initiated in patients greater than 80 years of age, unless measurement of creatinine clearance demonstrates that renal function is not significantly reduced. In patients with advance age, metformin should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function (see Part II, Action and Clinical Pharmacology, Pharmacokinetics, Special Populations and Conditions).

**Vitamin B<sub>12</sub> levels**
Impairment of vitamin B<sub>12</sub> and folic acid absorption has been reported in some patients treated with metformin. Therefore, measurements of serum vitamin B<sub>12</sub> and folic acid are advisable in patients on long-term treatment with GLUMETZA and GLUMETZA (SB).

**Monitoring and Laboratory Tests**
Periodic monitoring of fasting blood glucose and glycosylated hemoglobin levels may be useful in the long term management of patients with type 2 diabetes. During initial dose titration, fasting glucose can be used to determine the therapeutic dose response.

Initial and periodic monitoring of hematologic parameters (e.g. hemoglobin/hematocrit and red blood cell indices) and renal function (serum creatinine) should be performed, at least on an annual basis. While megaloblastic anemia has rarely been seen with metformin hydrochloride therapy, if this is suspected, vitamin B<sub>12</sub> deficiency should be excluded.

Particular attention should be paid to short range and long range complications which are peculiar to diabetes. Periodic cardiovascular, ophthalmic, hematological, hepatic and renal assessments are advisable (see Warnings and Precautions).
Hypoglycemia:
Hypoglycemia does not occur in patients receiving metformin hydrochloride alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents or alcohol. Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to hypoglycemic effect. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking beta-adrenergic blocking drugs.

Change in clinical status of previously controlled type 2 diabetes patient:
A diabetic patient previously well controlled on GLUMETZA and GLUMETZA (SB) who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose, and if indicated, blood pH, lactate, pyruvate and metformin levels. If acidosis of either form occurs GLUMETZA and GLUMETZA (SB) must be stopped immediately and appropriate corrective measures initiated (see Warnings and Precautions).

ADVERSE REACTIONS

Adverse Drug Reaction Overview
Gastrointestinal symptoms (GI) (diarrhea, nausea, vomiting) are common reactions to metformin hydrochloride treatment. These symptoms are generally transient and resolve spontaneously during continued treatment.

Additionally, as GI symptoms during therapy initiation appear to be dose-related, they may be decreased by gradual dose escalation and by having patients take their medication with meals.

Clinical Trial Adverse Drug Reactions
Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

In clinical trials conducted in the U.S., over 1000 patients with type 2 diabetes mellitus have been treated with GLUMETZA 1500 – 2000 mg/day in active-controlled and placebo-controlled studies.

Gastrointestinal disorders were the most frequently occurring events in all trials. Table 2 shows the combined incidence of gastrointestinal adverse events occurring in one Phase 2 study and one Phase 3 study comparing GLUMETZA to immediate-release metformin, coupled with the open label extension of the Phase 3 study.
Table 2  
Combined Gastrointestinal Adverse Events Occurring in at least 5% of Patients, in Three Clinical Trials*  

<table>
<thead>
<tr>
<th>System organ class/preferred term</th>
<th>Glumetza 1500 mg QD N=176 (%)</th>
<th>Glumetza 2000 mg QD N=279 (%)</th>
<th>Metformin IR 1500 mg am/pm N=174 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with at least one AE</td>
<td>133 (75.6)</td>
<td>222 (79.6)</td>
<td>136 (78.2)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>85 (48.3)</td>
<td>134 (48.0)</td>
<td>73 (42.0)</td>
</tr>
<tr>
<td>Diarrhea NOS</td>
<td>32 (18.2)</td>
<td>63 (22.6)</td>
<td>30 (17.2)</td>
</tr>
<tr>
<td>Nausea</td>
<td>30 (17)</td>
<td>41 (14.7)</td>
<td>24 (13.8)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>15 (8.5)</td>
<td>35 (12.5)</td>
<td>13 (7.5)</td>
</tr>
<tr>
<td>Vomiting NOS</td>
<td>14 (8.0)</td>
<td>15 (5.4)</td>
<td>6 (3.5)</td>
</tr>
<tr>
<td>Abdominal distention</td>
<td>5 (2.8)</td>
<td>22 (7.9)</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>Constipation</td>
<td>8 (4.5)</td>
<td>14 (5)</td>
<td>5 (2.9)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>13 (7.4)</td>
<td>12 (4.3)</td>
<td>7 (4.0)</td>
</tr>
</tbody>
</table>

* Combined data is from one Phase 2 study and one Phase 3 study comparing GLUMETZA to immediate-release metformin, coupled with the open label extension of the Phase 3 study.

In the Phase 3 trial comparing the safety and efficacy of GLUMETZA to metformin immediate-release tablets, all four treatment regimens (GLUMETZA at 1500 mg QD, 1500 mg BID, 2000 mg QD and Metformin IR 1500 mg BID) had comparable safety profiles. Patients in the once-daily treatment groups did not report any higher occurrence of adverse events than the twice daily treatment groups. The occurrence of GI adverse events was comparable between all treatment groups. All GLUMETZA treatment groups reported fewer occurrences of diarrhea and nausea than did the immediate-release treatment group during the first week of the titration period [1000 mg dose].

In the placebo-controlled study, patients receiving background glyburide (SU; sulfonylurea) therapy were randomized to receive add-on treatment of either one of three different regimens of GLUMETZA or placebo. In total, 431 patients received GLUMETZA + SU and 144 patients placebo + SU. Adverse events reported in greater than 5% of patients treated with GLUMETZA, that were more common in the combined GLUMETZA + SU group, than in the placebo + SU group, are shown in Table 3.
In 0.7% of patients treated with GLUMETZA + SU, diarrhea was responsible for discontinuation of study medication compared to zero in the placebo + SU group.

**Table 3** Treatment-Emergent Adverse Events Reported By >5%* of Patients for the Combined GLUMETZA Group Versus Placebo Group

<table>
<thead>
<tr>
<th>Adverse Event (Medra Preferred Term)</th>
<th>GLUMETZA + SU (n = 431)</th>
<th>Placebo + SU (n = 144)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoglycemia NOS</td>
<td>13.7%</td>
<td>4.9%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>12.5%</td>
<td>5.6%</td>
</tr>
<tr>
<td>Nausea</td>
<td>6.7%</td>
<td>4.2%</td>
</tr>
</tbody>
</table>

*AE's that were more common in the GLUMETZA-treated than in the placebo-treated patients.

In the same study, the following adverse events were reported by 1-5% of patients for the combined GLUMETZA group and these events occurred more commonly in the GLUMETZA-treated than in the placebo-treated patients:

*Ear and labyrinth disorders:* ear pain

*Gastrointestinal disorders:* vomiting NOS, dyspepsia, flatulence, abdominal pain upper, abdominal distension, abdominal pain NOS, toothache, loose stools

*General disorders and administration site conditions:* asthenia, chest pain

*Immune system disorders:* seasonal allergy

*Infections and infestations:* gastroenteritis viral NOS, tooth abscess, tonsillitis, fungal infection NOS

*Injury, poisoning and procedural complications:* muscle strain

*Musculoskeletal and connective tissue disorders:* pain in limb, myalgia, muscle cramp

*Nervous system disorders:* dizziness, tremor, sinus headache, hypoesthesia

*Respiratory, thoracic and mediastinal disorders:* nasal congestion

*Skin and subcutaneous tissue disorders:* contusion

*Vascular disorders:* hypertension NOS
**Uncommon Clinical Trial Adverse Drug Reactions (< 1%)**

The following adverse drug reactions were reported with <1% incidence in patients in any GLUMETZA treatment group in the placebo-controlled trial:

**Blood Disorders:** thrombocytopenia, neutropenia

**Eye disorders:** vision blurred

**Gastrointestinal disorders:** flatulence, gastric NOS, gastrointestinal upset, loose stools, vomiting NOS.

**General disorders and administration site conditions:** adverse drug reaction NOS, asthenia, chest pain, fatigue, lethargy, oedema aggravated, oedema peripheral, rigors.

**Infection and Infestations:** gastroenteritis viral NOS

**Investigations:** blood glucose decreased, liver function test abnormal NOS, muscle cramp, white blood cell count increased.

**Metabolism and Nutrition Disorders:** hyperglycemia NOS

**Nervous System Disorders:** dizziness, migraine NOS, parasthesia, syncope, tremor

**Reproductive System and Breast Disorders:** sexual dysfunction NOS

**Respiratory Disorders:** rhinorrhea, sinus congestion

**DRUG INTERACTIONS**

**Overview**

Certain drugs may potentiate the effect of metformin in the treatment of diabetes, particularly sulfonylureas, and the “glitazones” rosiglitazone and pioglitazone. This potentiating effect has expanded the number of combination drug therapies for type II diabetes, and improved HbA1c control. The simultaneous administration of potentiating drugs must be carefully monitored to prevent hypoglycemic reaction, especially if they are given to patients also receiving other drugs which can potentiate their effect. For example the effect of sulfonylureas can be potentiated by long-acting sulfonamides, tuberculostatics, phenylbutazone, clofibrate, monoamine oxidase inhibitors, salicylates, probenecid and propranolol. Metformin also potentiates the effect of insulin.

**GLUMETZA and sulfonylurea:** With concomitant GLUMETZA and sulfonylurea (SU) therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug. The influence of glyburide on GLUMETZA pharmacokinetics was assessed in a single-dose...
interaction study in healthy subjects. Co-administration of GLUMETZA and glyburide did not result in any changes in metformin pharmacokinetics, as AUC, $C_{\text{max}}$, and $T_{\text{max}}$, were unchanged. Changes in pharmacodynamics were not evaluated in this study (see Dosage and Administration: Concomitant GLUMETZA and Oral Sulphonylurea Therapy). In a clinical trial of patients with type 2 diabetes and prior treatment with glyburide, GLUMETZA plus glyburide combined therapy yielded a significant decrease from baseline to endpoint in mean HbA1c, relative to SU treatment alone (see Clinical Pharmacology, Clinical Studies). With concomitant GLUMETZA and sulfonylurea therapy, the risk of hypoglycemia associated with sulfonylurea therapy exists. Appropriate precautions should be taken. If patients have not satisfactorily responded to one to three months of concomitant therapy with the maximum dose of GLUMETZA and the maximum dose of an oral sulfonylurea, consider therapeutic alternatives including switching to insulin.

Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as compared to sulfonylureas, which are extensively bound to serum proteins.

In healthy volunteers, the pharmacokinetics of propranolol and ibuprofen were not affected by metformin when co-administered in single-dose interaction studies.

Drugs that have a tendency to produce hyperglycemia and may lead to a loss of blood sugar control include thiazide and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, estrogen plus proestrogen, oral contraceptive, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid. When such drugs are administered to patients receiving GLUMETZA and GLUMETZA (SB), the patient should be closely observed to maintain adequate glycemic control.

**Furosemide:** A single dose metformin - furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide increased the metformin plasma and blood $C_{\text{max}}$ by 22% and blood AUC by 15%, without any significant change in metformin renal clearance. When administered with metformin, the $C_{\text{max}}$ and AUC of furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin when co-administered chronically.

**Nifedipine:** A single dose metformin - nifedipine drug interaction study in healthy subjects demonstrated that co-administration of nifedipine increased plasma metformin $C_{\text{max}}$ and AUC by 20% and 9%, and increased the amount excreted in the urine. $T_{\text{max}}$ and half life were unaffected.

**Cationic Drugs:** (amiloride, cimetidine, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin) These drugs theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Such interaction has been observed between metformin and oral cimetidine in normal healthy volunteers in both single and multiple-dose, metformin-cimetidine drug interaction studies, with a 60% increase in peak metformin plasma and whole blood concentrations and a 40% increase in
plasma and whole blood metformin AUC was observed. The H2-blocker cimetidine competitively inhibits renal tubular secretion of metformin, significantly decreasing its clearance and increasing its bioavailability. There was no change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine pharmacokinetics. Therefore, careful patient monitoring and dose adjustment of metformin or the interfering drug is recommended in patients who are taking cationic medications that are excreted via renal tubular secretion.

Anticoagulant phenprocoumon: elimination rate of the anticoagulant phenprocoumon has been reported to be increased by 20% when used concurrently with metformin. Patients receiving phenprocoumon or other antivitamin K anticoagulants should be monitored carefully when both types of drugs are used simultaneously. In such cases, an important increase of prothrombin time may occur upon cessation of metformin therapy, with an increased risk of hemorrhage.

Drug-Food Interactions
GLUMETZA and GLUMETZA (SB) extended-release tablets have been formulated to be dosed with food. Both GLUMETZA and GLUMETZA (SB) extended-release tablets must be taken with food to ensure complete release and absorption of the metformin dose. In a single-dose study with the 500 mg tablet, when the product was given to healthy volunteers while fasting or with a high fat, or a AHA 30% low fat meal, AUC was increased significantly and a delay in T_max was observed when compared to the fasted state. The increase in AUC was significantly greater when the product was given with the high fat meal. There was no significant difference in C_max. In an open label pharmacoscintigraphic pharmacokinetic study in healthy volunteers, GLUMETZA 500 mg dosed with different fat content meals was evaluated. Both the gastric retention time and the systemic exposure of metformin were higher following the high fat meal than following the AHA 30% fat meal, demonstrating that prolonged gastric retention enables extended delivery of metformin.

Drug-Herb Interactions
Interactions with herbal products have not been established.

Drug-Laboratory Interactions
Interactions with laboratory tests have not been established.

Drug-Lifestyle Interactions
Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking GLUMETZA and GLUMETZA (SB), since alcohol intake potentiates the effect of metformin hydrochloride on lactate metabolism. (See Contraindications)

DOSAGE AND ADMINISTRATION

Dosing Considerations
GLUMETZA and GLUMETZA (SB) extended-release tablets must be taken with food to ensure optimum delivery of the metformin dose to the systemic circulation. (Please refer to Drug and Food interaction and Action and Clinical Pharmacology, Pharmacokinetics). In adult type 2
diabetic patients, individual determination of the minimum GLUMETZA and GLUMETZA (SB) dose that will adequately lower blood glucose should be made. There is no fixed metformin hydrochloride dosage regimen for the management of hyperglycemic patients.

In patients in whom the maximum recommended dose fails to lower the blood glucose adequately, the drug should be discontinued. In some diabetic subjects, short-term administration of the drug may be sufficient during periods of transient loss of blood sugar control.

**Recommended Dose and Dose Adjustment**

GLUMETZA and GLUMETZA (SB) therapy should usually be initiated at 1000 mg once-daily, taken with the evening meal. GLUMETZA and GLUMETZA (SB) extended-release tablets must be taken with food to ensure optimum delivery of the metformin dose to the systemic circulation. Gradual dose escalation in increments of 500 mg weekly are recommended, to reduce gastrointestinal side effects, and to permit identification of the minimum dose required for adequate glycemic control.

The maximum recommended dose is 2000 mg once daily, taken with the evening meal. Tablets should be taken whole, with a glass of water. During treatment initiation and dose titration, fasting plasma glucose should be used to determine the therapeutic response to GLUMETZA and GLUMETZA (SB), and to identify the minimum effective dose for the patients. Care should be taken in dose selection for the elderly, and should be based on careful and regular monitoring of renal function. Generally, elderly patients should not be titrated to the maximum dose of metformin.

**Transfer From Other Antidiabetic Therapy**

When transferring patients from standard oral hypoglycemic agents, other than chlorpropamide, to GLUMETZA or GLUMETZA (SB), no transition period generally is necessary. Patients treated with immediate release metformin have been switched to GLUMETZA or GLUMETZA (SB) once daily without incident. (Part II, Scientific Information, Clinical Trials) Following switching, from the IR formulation to GLUMETZA or GLUMETZA (SB), glycemic control should be closely monitored and dosage adjustments made accordingly. When transferring patients from chlorpropamide, care should be exercised during the first two weeks because of the prolonged retention of chlorpropamide in the body, leading to overlapping drug effects and possible hypoglycemia.

**Concomitant GLUMETZA or GLUMETZA (SB) and Oral Sulfonylurea Therapy in Adult Patients**

If patients have not responded to four weeks of the maximum dose of GLUMETZA or GLUMETZA (SB) monotherapy, consideration should be given to gradual addition of oral sulfonylurea while continuing GLUMETZA or GLUMETZA (SB) at the maximum dose, even if prior primary or secondary failure to a sulfonylurea has occurred. With concomitant metformin and sulfonylurea therapy, the desired control of blood glucose may be obtained by
adjusting the dose of each drug. In a clinical trial of patients with type 2 diabetes and prior
treatment with glyburide, 15 mg/day, the efficacy of GLUMETZA in combination with
glyburide was compared to the efficacy of glyburide alone (placebo), to achieve glycemic
control as measured by significant reductions from baseline in FPG, HbA1c, fructosamine and
blood glucose response (Part II: Scientific Information, Clinical Trials). The minimum effective
dose of each drug should be identified. With concomitant GLUMETZA or GLUMETZA (SB)
and sulfonylurea therapy, there is risk of hypoglycemia. Appropriate precautions should be
taken. (See Package Insert of the respective sulfonylurea). If patients have not satisfactorily
responded to one to three months of concomitant therapy with the maximum dose of
GLUMETZA or GLUMETZA (SB) and the maximum dose of an oral sulfonylurea, consider
therapeutic alternatives including switching to insulin.

**Missed Dose**

If a dose of GLUMETZA or GLUMETZA (SB) is missed, it should be taken as soon as
possible, with food. However, if it is less than ten hours before the next dose, skip the missed
dose and go back to the regular dosing schedule. Do not double doses. If patients do not feel
well, or home glucose testing shows elevated levels, a physician should be contacted.

**Administration**

GLUMETZA and GLUMETZA (SB) extended-release tablets must be taken with food, and
should be taken whole, with a glass of water.

Do not break or crush tablets.

**OVERDOSAGE**

Overdose with GLUMETZA and GLUMETZA (SB) has not been reported. It would be
expected that adverse reactions of a more intense character, including epigastric discomfort,
nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and
headache might be seen. Should those symptoms persist, the presence of lactic acidosis should
be excluded. Immediate contact with a physician should be made, to determine if treatment
should be stopped and proper supportive therapy instituted. For management of a suspected
drug overdose, contact your regional Poison Control Centre.

Overdose of metformin hydrochloride has been reported, including ingestion of amounts greater
than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal
association with metformin hydrochloride has been established. Lactic acidosis has been
reported in approximately 32% of metformin overdose cases (see Warnings and Precautions).
Metformin is dialyzable with clearance of up to 170 mL/min under good hemodynamic
conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from
patients in whom metformin overdosage is suspected.
ACTION AND CLINICAL PHARMACOLOGY

Pharmacodynamics
Metformin hydrochloride is a biguanide anti-hyperglycemic agent, which is widely used for the treatment of type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus [NIDDM]. Metformin improves glycemic control by enhancing insulin sensitivity in liver and muscle, and reducing gastrointestinal glucose absorption and hepatic glucose production. However it does not stimulate insulin secretion and, therefore, is not associated with hypoglycemia. Improved metabolic control with metformin does not induce weight gain and may cause weight loss. It has been demonstrated that the favorable effects of metformin also include improvements in factors associated with cardiovascular risk including lipids, fibrinolysis and body weight.

Mechanism of Action
Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects (except in special circumstances, (see Warnings and Precautions) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.

At therapeutic doses, metformin does not lower plasma glucose levels in non-diabetic animals or humans. Oral administration of metformin was demonstrated to effectively lower plasma glucose levels in streptozocine-induced diabetic mice, genetically diabetic KK mice, obese female fa/fa rats, and alloxan-induced diabetic rats. In addition to its antihyperglycemic effects, metformin has been shown to have hypolipidemic effects and to significantly improve the progression and regression of atherosclerotic lesions. Metformin has also been shown to reduce blood pressure in spontaneously hypertensive rats, either through sympathoinhibitory effects, a direct effect on vascular smooth muscle responsiveness to norepinephrine, and/or attenuation of hyperinsulinemia.

The antihyperglycemic effect of metformin does not appear to be due to effects on plasma insulin or glucagon concentrations. While some studies have demonstrated that metformin produces an increase in insulin receptor binding or an increase in low-affinity receptor number, it is generally accepted that the antihyperglycemic effects of metformin are poorly correlated with insulin binding and its effects on receptor binding and number are not directly related to its metabolic and clinical effects. A direct effect of metformin on insulin secretion has been ruled out as a mechanism for the antihyperglycemic effects because metformin does not increase circulating levels of insulin nor has it been shown experimentally to stimulate insulin secretion. Although the precise mechanism of hypoglycemic action of metformin remains unclear, it likely interrupts mitochondrial oxidative processes in the liver and corrects abnormalities of intracellular calcium metabolism in insulin-sensitive tissues (liver, skeletal muscle, and adipocytes) and cardiovascular tissue.
 Pharmacokinetics

GLUMETZA pharmacokinetics have been characterized after oral administration of single and multiple doses to adult healthy volunteers, in eleven separate studies.

Absorption:

Following a single oral dose of 1000 mg GLUMETZA extended-release Tablets once-daily after a meal, the time to reach maximum plasma metformin concentration ($T_{\text{max}}$) is approximately 7 - 8 hours. In both single and multiple dose studies in healthy subjects, once daily 1000 mg dosing provides equivalent systemic exposure, as measured by area-under-the-curve (AUC), of metformin relative to the immediate release given as 500 mg twice daily.

Once daily oral doses of GLUMETZA 500 mg to 2500 mg doses resulted in less than proportional increases in both AUC and $C_{\text{max}}$. The mean $C_{\text{max}}$ values were 473 ± 145, 868 ± 223, 1171 ± 297, and 1630 ± 399 ng/mL for once daily doses of 500, 1000, 1500, and 2500 mg, respectively. For AUC, the mean values were 3501 ± 796, 6705 ± 1918, 9299 ± 2833, and 14161 ± 4432 ng.hr/mL for once daily doses of 500, 1000, 1500, and 2500 mg, respectively.

Low-fat and high-fat meals increased the systemic exposure (as measured by AUC) from GLUMETZA extended-release tablets by about 38% and 73%, respectively, relative to fasting. Both meals prolonged metformin $T_{\text{max}}$ by approximately 3 hours, but $C_{\text{max}}$ was not affected. In an open label pharmacoscintigraphic pharmacokinetic study in healthy volunteers, GLUMETZA 500 mg dosed with different fat content meals was evaluated. Both the gastric retention time and the systemic exposure of metformin were higher following the high fat meal than following the AHA 30% fat meal, demonstrating that extended gastric retention enables extended delivery of metformin. For transit times less than 7 hours as sometimes seen in AHA 30% fat meal administration, absorption of metformin may be decreased almost linearly with decreasing upper GI transit time.

Distribution:

The apparent volume of distribution ($V/F$) of metformin, following single oral doses of 850 mg immediate-release metformin hydrochloride averaged 654 ± 358 L. At doses of 500 to 1500 mg, metformin has an absolute oral bioavailability of 50% to 60%. The drug is not protein bound and therefore has a wide volume of distribution, with maximal accumulation in the small intestine wall. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin, steady state plasma concentrations of metformin are reached within 24-48 hours and are generally < 1 μg/mL.

Metabolism:

Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion. Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is
eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.

**Excretion:**
Metformin undergoes no modifications in the body and is secreted unchanged by rapid kidney excretion (through glomerular filtration and, possibly, tubular secretion). Impaired kidney function slows elimination, and may cause metformin accumulation.

The apparent plasma elimination half-life of metformin following a single dose of GLUMETZA tablets is approximately 8 hours. Results from a dose proportionality study involving once daily oral doses of GLUMETZA 500 mg to 2500 mg, indicate a lack of dose proportionality with increasing doses, as both AUC and C\textsubscript{max} increased nonlinearly within the investigated dose range.

Concomitant administration with glyburide (Diaβeta\textsuperscript{®}) does not lead to a change in the peak and systemic exposures of metformin. *(Part II: Scientific Information, Clinical Trials)*

**Special Populations and Conditions**

**Pediatrics:**
No pharmacokinetic studies of GLUMETZA or GLUMETZA (SB) in pediatric subjects were conducted.

**Geriatrics:**
Limited data from controlled pharmacokinetic studies of metformin hydrochloride in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged and C\textsubscript{max} is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function *(see Warnings and Precautions, Special Populations)*.

**Gender:**
In the pharmacokinetic studies in healthy volunteers, there were no important differences between male and female subjects with respect to metformin AUC (males = 268, females = 293) and t\textsubscript{1/2} (males = 229, females = 260). However, C\textsubscript{max} for metformin were somewhat higher in female subjects (Female/Male C\textsubscript{max} Ratio = 1.4). The gender differences for C\textsubscript{max} are unlikely to be clinically important.

**Race**
There were no definitive conclusions on the differences between the races with respect to the pharmacokinetics of GLUMETZA because of the imbalance in the respective sizes of the racial groups. However, the data suggest a trend towards higher metformin C\textsubscript{max} and AUC values for metformin are obtained in Asian subjects when compared to Caucasian, Hispanic and Black subjects. The differences between the Asian and Caucasian groups are unlikely to be clinically important.
**Hepatic Insufficiency:** No pharmacokinetic studies of GLUMETZA or GLUMETZA (SB) have been conducted in patients with hepatic insufficiency.

**Renal Insufficiency:**
In patients with decreased renal function (based on measured serum creatinine) the blood half-life of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance.

**STORAGE AND STABILITY**
GLUMETZA and GLUMETZA (SB) (metformin hydrochloride extended-release) tablets are to be stored at 15°C - 30°C.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**
GLUMETZA extended-release tablets are available in 500 mg and 1000 mg strengths. Each GLUMETZA 500 mg extended-release tablet also contains: hypromellose, microcrystalline cellulose, magnesium stearate, polyethylene glycol, polyethylene oxide, polysorbate, titanium dioxide. GLUMETZA 500 mg tablets are white, film coated, oval-shaped, debossed with ‘M 500’.

Each GLUMETZA 1000 mg extended-release tablet also contains: colloidal silicon dioxide, crospovidone, glyceryl behenate, polyvinyl alcohol, polyacrylate dispersion, hypromellose, talc, polyethylene glycol, titanium dioxide, simethicone emulsion, polysorbate, shellac glaze, iron oxide black, macrogol, n-butyl alcohol, propylene glycol, FD&C blue #2, FD&C yellow#6 and FD&C red #40. GLUMETZA 1000 mg tablets are white, oval-shaped, printed with ‘M 1000’.

Each GLUMETZA (SB) 1000 mg extended-release tablet also contains: colloidal silicon dioxide, crospovidone, dibutyl sebacate, ethylcellulose, glyceryl behenate, polyvinyl alcohol, povidone. GLUMETZA (SB) 1000 mg tablets are white, oval-shaped, printed with ‘M 1000’.

GLUMETZA 500 mg: bottles of 30’s, 100’s, and 500’s
GLUMETZA 1000 mg: bottles of 7’s, 30’s, and 90’s
GLUMETZA (SB) 1000 mg: bottles of 30’s, 90’s, 500’s, and 1000’s
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: metformin hydrochloride

Chemical Name: 1,1-dimethylbiguanide hydrochloride

Molecular Formula and Molecular Mass: $C_4H_{11}N_5\cdot HCl$  $\text{MW 165.63}$

Structural formula:

![Structural formula of metformin hydrochloride]

Physiochemical Properties:

Metformin hydrochloride is a white to off-white crystalline compound with a molecular formula of $C_4H_{11}N_5\cdot HCl$ and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKₐ of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. GLUMETZA and GLUMETZA (SB) tablets are modified release dosage forms that contain 500 mg or 1000 mg of metformin hydrochloride.
CLINICAL TRIALS
Study Demographics and Trial Design

Four clinical studies were conducted in patients with type 2 diabetes, to establish the safety and efficacy of GLUMETZA extended-release tablets, as shown in the following Table 4.

Table 4  GLUMETZA Safety and Efficacy Trials

<table>
<thead>
<tr>
<th>Trial Design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n = number)</th>
<th>Mean age (range)</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 2, randomized, double-blind, parallel-group, active-controlled, dose-escalation, multicentre</td>
<td>1000 - 2,000 mg/day, orally for 4 weeks</td>
<td>163</td>
<td>54.6 (31-77)</td>
<td>83 M/ 80 F</td>
</tr>
<tr>
<td>Phase 3, randomized, double-blind, parallel-group, active-controlled, non-inferiority, multicentre</td>
<td>1500 - 2000 mg/day, orally for 24 weeks</td>
<td>706</td>
<td>54 (24-79)</td>
<td>380 M/ 326 F</td>
</tr>
<tr>
<td>Open-label, phase 3 extension to Study 81-0003, randomized, double-blind, active uncontrolled, multicentre</td>
<td>2000 mg orally for 24 weeks</td>
<td>245</td>
<td>56 (26-78)</td>
<td>135 M/ 110 F</td>
</tr>
<tr>
<td>Phase 3, randomized, double-blind, parallel-group, active placebo-controlled (add-on), multicentre</td>
<td>1500 - 2000 mg/day, orally for 24 weeks</td>
<td>575</td>
<td>53 (25-80)</td>
<td>314 M/ 261 F</td>
</tr>
</tbody>
</table>

In a multicenter, randomized, double-blind, active-controlled, dose-ranging, parallel group study of GLUMETZA 1500 mg once a day, GLUMETZA 1500 mg per day in divided doses (500 mg in the morning and 1000 mg in the evening), and GLUMETZA 2000 mg once a day were compared to immediate release (IR) metformin 1500 mg per day in divided doses (500 mg in the morning and 1000 mg in the evening) (Table 5). Metformin IR treatment was initiated as 500 mg BID for 1 week followed by 500 mg with breakfast and 1000 mg with dinner from the second week. The 3-week titration period was followed by an additional 21-week period at the randomized dose. Each of the GLUMETZA regimens, were at least as effective as metformin IR in all measures of glycemic control. Once daily dosing of GLUMETZA was as effective as the commonly prescribed twice daily dosing of the immediate-release product.
**Table 5**  Mean±SE Changes from Baseline to Final Visit in HbA1c, Fasting Plasma Glucose and Body Weight for the GLUMETZA and Metformin IR Treatment Groups (24-Week Study)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>GLUMETZA 1500 mg QD (n = 178)</th>
<th>GLUMETZA 1500 mg AM/PM (n = 182)</th>
<th>Metformin IR 1500 mg AM/PM (n = 174)</th>
<th>Overall Treatment p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HbA1c (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>169</td>
<td>175</td>
<td>159</td>
<td>170</td>
</tr>
<tr>
<td>Baseline</td>
<td>8.22 ± 0.25</td>
<td>8.50 ± 0.24</td>
<td>8.26 ± 0.24</td>
<td>8.70 ± 0.25</td>
</tr>
<tr>
<td>Mean Change ±SE at Final Visit</td>
<td>-0.73 ± 0.12</td>
<td>-0.74 ± 0.12</td>
<td>-1.06 ± 0.12</td>
<td>-0.70 ± 0.12</td>
</tr>
<tr>
<td>Mean Difference ± SE from Metformin IR</td>
<td>-0.03 ± 0.12</td>
<td>-0.04 ± 0.12</td>
<td>-0.36 ± 0.12</td>
<td>N/A</td>
</tr>
<tr>
<td>98.4% CI for Difference</td>
<td>(-0.32, 0.26)</td>
<td>(-0.33, 0.25)</td>
<td>(-0.65, -0.06)</td>
<td></td>
</tr>
</tbody>
</table>

| Fasting Plasma Glucose (mg/dL)   |                                |                                 |                                    |                          |
| n                                | 175                            | 179                             | 170                                | 172                      |
| Baseline                         | 190.0 ± 9.9                    | 192.5 ± 9.9                     | 183.9 ± 9.9                        | 196.5 ± 11.2             | 0.855                    |
| Mean Change ± SE at Final Visit  | -38.5 ± 4.4                    | -31.8 ± 4.4                     | -42.0 ± 4.5                        | -32.1 ± 4.5              | 0.051                    |
| Mean Difference ± SE from Metformin IR | -6.4 ±4.4                     | 0.2 ± 4.3                      | -9.9 ± 4.4                         | N/A                      |
| 95% CI for Difference            | (-15.0, 2.1)                   | (-8.3, 8.7)                     | (-18.5, -1.3)                      |                          |

| Body Weight (kg)                 |                                |                                 |                                    |                          |
| n                                | 176                            | 180                             | 171                                | 173                      |
| Baseline                         | 88.17 ± 3.66                   | 90.50 ± 3.66                    | 87.73 ± 3.66                       | 88.72 ± 3.87             | 0.954                    |
| Mean Change ± SE at Final Visit  | -0.93 ± 0.40                   | -0.68 ± 0.40                    | -1.10 ± 0.40                       | -0.85 ±0.41              | 0.753                    |
| Mean Difference ± SE from Metformin IR | -0.09 ± 0.40                   | 0.17 ± 0.39                    | -0.26 ± 0.40                       | N/A                      |
| 95% CI for Difference            | (-0.86, 0.69)                  | (-0.61, 0.94)                   | (-1.04, 0.52)                      |                          |

Patients who completed this 24-week study were placed on GLUMETZA 2000 mg/day treatment during a 24-week open-label trial in order to evaluate the long-term safety and duration of effectiveness of GLUMETZA. This resulted in the exposure of 158 patients to continuous treatment with GLUMETZA 1500-2000 mg/day (56 on 2000 mg/day) for a cumulative period of 48 weeks. GLUMETZA treatment maintained steady levels of HbA1c, FPG and plasma fructosamine over the 24 week period from the open-label baseline to the open-label endpoint. All treatment groups irrespective of previous treatment in the double-blind study, showed similar decreases in HbA1c, FPG and plasma fructosamine levels over the cumulative 48 week period from the double-blind baseline to the open-label phase.

In a double-blind, randomized, placebo-controlled (add-on), multicentre study, patients with type 2 diabetes mellitus who were newly diagnosed or treated with diet and exercise, or who were receiving monotherapy with metformin, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, or meglinitides, or treated with combination therapy consisting of
metformin/glyburide at doses up to 1000 mg metformin + 10 mg glyburide per day (or equivalent doses of glipizide or glimepiride up to half the maximum therapeutic dose) were enrolled. They were stabilized on glyburide for a 6-week period, and then randomized to 1 of 4 treatments: placebo + glyburide (glyburide alone); GLUMETZA 1500 mg once a day + glyburide, GLUMETZA 2000 mg once a day + glyburide, or GLUMETZA 1000 mg twice a day + glyburide. A 3-week GLUMETZA titration phase was followed by a 21-week maintenance treatment phase. There was a decrease from Baseline to Endpoint in mean HbA1c levels in the GLUMETZA + glyburide groups (mean change, -0.74%; 95% CI, -0.85, -0.64), but almost no change in the glyburide only group (mean change 0.08%; 95% CI, -0.08, 0.25). (See Table 6). The difference in the change from Baseline in HbA1c levels between the combined M-ER+ SU groups and the SU only group was statistically significant (p<0.001). The changes in glycemic control across the three GLUMETZA+glyburide groups were comparable.

**Table 6  Mean±SE Changes from Baseline to Final Visit in HbA1c, Fasting Plasma Glucose and Body Weight for the Combined GLUMETZA/Glyburide and Placebo/Glyburide Treatment Groups (24-Week Study)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Combined GLUMETZA/Glyburide Groups (n = 431)</th>
<th>Placebo/Glyburide Group (n = 144)</th>
<th>Overall Treatment p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>416</td>
<td>141</td>
<td>0.051</td>
</tr>
<tr>
<td>Baseline</td>
<td>7.79 ± 0.07</td>
<td>8.08 ± 0.13</td>
<td></td>
</tr>
<tr>
<td>Mean Change ± SE at Final Visit</td>
<td>-0.74 ± 0.05</td>
<td>-0.08 ± 0.08</td>
<td></td>
</tr>
<tr>
<td>Mean Difference ± SE from Glyburide Alone</td>
<td>-0.82 ± 0.09</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>95% CI for Difference</td>
<td>(-1.00, -0.65)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-value for pairwise comparison</td>
<td>&lt; 0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>429</td>
<td>144</td>
<td>0.719</td>
</tr>
<tr>
<td>Baseline</td>
<td>162.0 ± 2.7</td>
<td>164.0 ± 4.7</td>
<td></td>
</tr>
<tr>
<td>Mean Change ± SE at Final Visit</td>
<td>-13.0 ± 2.4</td>
<td>15.4 ± 3.7</td>
<td></td>
</tr>
<tr>
<td>Mean Difference ± SE from Glyburide Alone</td>
<td>-28.4 ± 4.0</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>95% CI for Difference</td>
<td>(-36.2, -20.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-value for pairwise comparison</td>
<td>&lt; 0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body Weight (kg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>430</td>
<td>144</td>
<td>0.762</td>
</tr>
<tr>
<td>Baseline</td>
<td>98.66 ± 6.46</td>
<td>95.56 ± 7.94</td>
<td></td>
</tr>
<tr>
<td>Mean Change ± SE at Final Visit</td>
<td>0.16 ± 1.01</td>
<td>0.77 ± 1.04</td>
<td></td>
</tr>
<tr>
<td>Mean Difference ± SE from Glyburide Alone</td>
<td>-0.60 ± 0.43</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>95% CI for Difference</td>
<td>(-1.45, 0.24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-value for pairwise comparison</td>
<td>0.16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Glyburide was administered as 10 mg at breakfast and 5 mg at dinner.

**DETAILED PHARMACOLOGY**

The mechanism of the antihyperglycemic effect of metformin is not completely understood and probably several actions are involved. The following mechanisms of action have been suggested: 1) increased insulin receptor binding; 2) decreased intestinal glucose absorption; 3) increased cellular glucose uptake; 4) decreased hepatic gluconeogenesis; 5) stimulation of anaerobic glycolysis; and 6)
potentiation of insulin action at the receptor or post-receptor level.

At therapeutic doses, metformin does not lower plasma glucose levels in non-diabetic animals or humans. However, oral administration of metformin was shown to effectively lower plasma glucose levels in several different animal models of hyperglycemia, including streptozotocin-induced diabetic mice, genetically diabetic KK mice, obese female fa/fa rats, and alloxan-induced diabetic rats. Metformin does not reduce basal glucose concentrations below the normal physiological range, either in diabetic animals or humans.

The antihyperglycemic effect of metformin does not appear to be due to effects on plasma insulin or glucagon concentrations. While some studies have demonstrated that metformin produces an increase in insulin receptor binding or an increase in low-affinity receptor number, it is generally accepted that the antihyperglycemic effects of metformin are poorly correlated with insulin binding, and its effects on receptor binding and number are not directly related to its metabolic and clinical effects. A direct effect of metformin on insulin secretion has been ruled out as a mechanism for the antihyperglycemic effects because metformin does not increase circulating levels of insulin nor has it been shown experimentally to stimulate insulin secretion.

Animal studies have demonstrated that metformin inhibits intestinal glucose absorption in both normal and diabetic animals, although the concentrations necessary to produce this effect are usually higher than the therapeutic range. The inhibition of intestinal glucose absorption does not appear to account for the full ability of metformin to reduce glycemia, indicating that other mechanisms of action play a role. The effect of metformin on glucose absorption has not been confirmed in diabetic patients.

Several studies have been conducted, both in vitro and in vivo, to determine the effects of metformin on glucose uptake into tissues, glucose oxidation, and glycogen synthesis. In general, metformin potentiates insulin-mediated glucose uptake into tissues, with the skeletal muscle being the most important site. This effect of metformin appears to be due to facilitation of a post-receptor sensitivity to insulin. Metformin was shown to have no effect on basal or insulin-stimulated glucose oxidation in muscle from non-diabetic mice but potentiated glucose oxidation in muscle from streptozotocin-diabetic mice in the presence of insulin. Metformin also increased basal glucose oxidation in adipocytes from non-diabetic rats. The results of studies on glycogen synthesis have been less consistent, with metformin producing either no effect or an increase in insulin-stimulated glycogen synthesis in skeletal muscle of non-diabetic and diabetic animals.

Many studies in diabetic animals and human diabetic patients have demonstrated that metformin improves glucose tolerance, an effect that is less pronounced or absent in non-diabetic individuals. Studies at the cellular level indicate that metformin potentiates insulin action and results from in vitro studies support a post-receptor mechanism of action.

In addition to antihyperglycemic effects, metformin has been shown to have hypolipidemic effects and to significantly improve the progression and regression of atherosclerotic lesions. Metformin has been shown to be effective in inhibiting fructose- and fat-induced hypertriglyceridemia; it appears that metformin inhibits the transfer of dietary triglyceride from the gastrointestinal tract into plasma and reduces the uptake of the absorbed lipid by adipose tissue.
Several studies were conducted to determine the effects of metformin on the lipoprotein composition of VLDL from normal and cholesterol-fed animals. The results indicated that metformin produced changes in the lipoprotein composition in cholesterol-fed animals toward a more normal composition. In addition, it produced structural modifications of VLDL that led to a rapid turnover and a decreased interaction with arterial wall binding components. Metformin also altered lipid metabolism in the aortic wall, inhibiting intramural lipid biosynthesis.

Metformin has been shown to reduce blood pressure in spontaneously hypertensive rats. The suggested mechanisms involved in this effect include a sympathoinhibitory effect, a direct effect on vascular smooth muscle responsiveness to norepinephrine, and attenuation of hyperinsulinemia.

Several drug interaction studies with metformin were available in the scientific literature. Metformin was shown to enhance the elimination of phenprocoumon in diabetic patients. Because studies in rats did not demonstrate any effect of metformin on liver microsomal enzymes, it was postulated that an increase in liver blood flow might explain the drug interaction between metformin and phenprocoumon. Metformin was also shown to counteract the hyperglycemic effects of diazepam and nifedipine.

**TOXICOLOGY**

A comprehensive nonclinical toxicology program was conducted with metformin, including repeat-dose toxicity studies in rats and dogs, a battery of genotoxicity studies, two carcinogenicity studies, and a full assessment of reproductive toxicity studies.

An overview of the nonclinical toxicology program conducted with metformin hydrochloride is presented in Table 7 below.
<table>
<thead>
<tr>
<th>Study Type/Name</th>
<th># of Animals</th>
<th>Doses</th>
<th>NOAEL</th>
<th>Species/Strain</th>
<th>Route of Admin.</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic Toxicity Testing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26-week study in rats</td>
<td>160</td>
<td>150, 450, 900 mg/kg/day</td>
<td>150 mg/kg/day</td>
<td>Rats / Sprague-Dawley</td>
<td>Oral / Gavage</td>
<td>Decrease in body weight gains at 450 and 900 mg/kg/day, changes in clinical laboratory parameters (decreased total leukocyte, lymphocyte and neutrophil count) and in some organ weights at 900 mg/kg/day.</td>
</tr>
<tr>
<td>39-week study in dogs</td>
<td>32</td>
<td>20, 40, 60, 80 mg/kg/day</td>
<td>80 mg/kg/day</td>
<td>Dogs / Beagle</td>
<td>Oral / Capsule</td>
<td>Treatment-related effects in food consumption seen in females only at 80 mg/kg/day.</td>
</tr>
<tr>
<td>Carcinogenicity Testing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26-week carcinogenicity study in transgenic mice</td>
<td>150</td>
<td>500, 1000, 2000 mg/kg/day</td>
<td>-</td>
<td>Mice / Tg.AC</td>
<td>Dermal</td>
<td>No findings. No papillomas at treatment sites.</td>
</tr>
<tr>
<td>104-week carcinogenicity study in rats</td>
<td>400</td>
<td>males: 150, 300, 450 mg/kg/day females: 150, 450, 900, 1200 mg/kg/day</td>
<td>450 mg/kg/day</td>
<td>Rats / Sprague-Dawley</td>
<td>Oral / Gavage</td>
<td>Parathyroid hyperplasia in males at all doses, and not noted for females. Non-neoplastic findings seen in females and not with males. No tumorigenicity. Increase in female kidney weights at 900 and 1200 mg/kg/day.</td>
</tr>
<tr>
<td>Genotoxicity Testing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMES Assay</td>
<td>N/A</td>
<td>100, 333, 1000, 5000 mcg/plate</td>
<td>-</td>
<td>Salmonella / E.coli</td>
<td>N/A</td>
<td>Negative</td>
</tr>
<tr>
<td>In vitro cytogenetics – mouse lymphoma assay</td>
<td>N/A</td>
<td>1000, 2000, 3000, 4000, 5000 mcg/plate</td>
<td>-</td>
<td>Mice / Lymphoma cells</td>
<td>N/A</td>
<td>Negative</td>
</tr>
<tr>
<td>In vivo cytogenetics – mouse micronucleus assay</td>
<td>70</td>
<td>500, 1000, 2000 mg/kg</td>
<td>-</td>
<td>ICR mice</td>
<td>Oral / Gavage</td>
<td>Negative</td>
</tr>
<tr>
<td>Reproductive Toxicity Testing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Segment I/II toxicity study in rats (Fertility &amp; developmental toxicity)</td>
<td>200</td>
<td>150, 450, 900 mg/kg/day</td>
<td>900 mg/kg/day</td>
<td>Rats / Sprague-Dawley; 100 males &amp; 100 females</td>
<td>Oral / Gavage</td>
<td>Decrease in male reproductive organ weights at 900 mg/kg/day.</td>
</tr>
<tr>
<td>Segment III toxicity study in rats (Pre- and postnatal toxicity)</td>
<td>100</td>
<td>150, 300, 600 mg/kg/day</td>
<td>150 mg/kg/day</td>
<td>Rats / Sprague-Dawley; Mated females</td>
<td>Oral / Gavage</td>
<td>Decrease in F1 female body weight and feed consumption at 300 and 600 mg/kg/day.</td>
</tr>
<tr>
<td>Segment II toxicity study in rabbits (Developmental toxicity in rabbits)</td>
<td>80</td>
<td>30, 60, 90 mg/kg/day</td>
<td>&gt; 90 mg/kg/day</td>
<td>Rabbits / New Zealand white Time Pregnant females</td>
<td>Oral / Stomach tube</td>
<td>No effects on gross external, soft tissue, or skeletal malformation.</td>
</tr>
<tr>
<td>Bridging Study with Final Dosage Form</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bridging study in dogs</td>
<td>70</td>
<td>250, 500, 1000 mg/day</td>
<td>250 mg/day</td>
<td>Beagle dogs</td>
<td>Oral</td>
<td>Severe weight loss and clinical signs at doses 500 mg/day and higher.</td>
</tr>
</tbody>
</table>
REFERENCES


Altuntas Y, Ozen B, Ozturk B, Sengul A, Ucak S, Ersoy O, Karul S. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin in secondary OAD failure. Diabetes, Obesity and Metabolism 2003; 5:371-378


Fujita H, Narita T, Yoshioka N, Hosoba M, Ito S. A case of megaloblastic anemia due to vitamin B12 deficiency precipitated in a totally gastrectomized type II diabetic patient following the introduction of metformin therapy. Endocr J 2003;50:483-484


Scarpello JHB. Improving survival with metformin: the evidence base today. Diabetes Metab 2003, 29, 6S36-6S43.


Vague P. Is metformin more than an oral hypoglycaemic agent? Diabetes Metab. 2003, 29, 6S5-6S7.


PART III: CONSUMER INFORMATION

GLUMETZA® and GLUMETZA® (SB)
(metformin hydrochloride extended-release tablets)

This leaflet is part III of a three-part "Product Monograph" published when GLUMETZA and GLUMETZA (SB) were approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about GLUMETZA and GLUMETZA (SB). Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
GLUMETZA and GLUMETZA (SB) extended-release tablets are used in addition to diet and exercise, to improve blood sugar levels in adults with type 2 diabetes. People with type 2 diabetes are not able to make enough insulin and they do not respond normally to the insulin that their bodies make.

What it does:
GLUMETZA and GLUMETZA (SB) (metformin hydrochloride) extended-release tablets work to control your blood sugar by:
- helping insulin, naturally produced by your body, be more effective.
- decreasing the amount of sugar your liver makes.
- decreasing the amount of sugar your intestines absorb.

When it should not be used:
Do not use GLUMETZA and GLUMETZA (SB) if:
- You have a known allergy to metformin or any ingredients found in GLUMETZA and GLUMETZA (SB) extended-release tablets
- You have unstable or Type 1 (insulin dependent) diabetes
- You have acute or chronic metabolic acidosis or diabetic ketoacidosis, with or without coma
- You have a history of lactic acidosis
- You have severe liver dysfunction
- You have cardiovascular collapse or cardiopulmonary insufficiency
- You have kidney disease or impairment
- You drink alcohol
- You are going to have an x-ray procedure with injection of iodinated contrast materials
- Prior to surgery or during your recovery phase
- You have a severe infection
- You have severe dehydration (have lost a lot of water from your body)
- You are pregnant or planning to become pregnant

What the medicinal ingredient is:
Each tablet contains 500mg or 1000mg metformin hydrochloride.

What the important nonmedicinal ingredients are:
GLUMETZA 500 mg: hypromellose, microcrystalline cellulose, magnesium stearate, polyethylene glycol, polyethylene oxide, polysorbate, titanium dioxide.
GLUMETZA 1000 mg: colloidal silicon dioxide, crospovidone, glyceryl behenate, polyvinyl alcohol, polyacrylate dispersion, hypromellose, talc, polyethylene glycol, titanium dioxide, simethicone emulsion, polysorbate, shellac glaze, iron oxide black, macrogol, n-butyl alcohol, propylene glycol, FD&C blue #2, FD&C yellow #6 and FD&C red #40.
GLUMETZA (SB) 1000 mg: colloidal silicon dioxide, crospovidone, dibutyl sebacate, ethylcellulose, glyceryl behenate, polyvinyl alcohol, povidone.

For a full listing of nonmedicinal ingredients see Part 1 of the product monograph.

What dosage forms it comes in:
Extended Release tablets: Each tablet contains 500mg or 1000mg metformin hydrochloride.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions
GLUMETZA and GLUMETZA (SB) may rarely be associated with a serious, life-threatening condition called lactic acidosis (see Lactic Acidosis below).

You should not drink a lot of alcohol if you take GLUMETZA or GLUMETZA (SB) (see section Lactic Acidosis below).

BEFORE you use GLUMETZA and GLUMETZA (SB) talk to your doctor or pharmacist if you have:
- a history of kidney disease
IMPORTANT: PLEASE READ

- are 80 years or older and you have NOT had your kidney function tested
- liver disease
- metabolic acidosis (e.g. diabetic ketoacidosis)
- recent heart attack
- recent stroke
- serious infection
- dehydration
- scheduled surgery
- scheduled x-ray or scanning procedures
- are pregnant, breast-feeding or planning to become pregnant
- vitamin B12 or folic acid deficiency
- drink alcohol

Lactic Acidosis
GLUMETZA or GLUMETZA (SB) therapy may rarely be associated with a serious, life-threatening condition called lactic acidosis.

Due to potential for lactic acidosis, you should talk to your doctor if you take GLUMETZA or GLUMETZA (SB) and if you:
- develop or experience a worsening of heart disease and particularly heart failure
- develop a serious medical condition, such as heart attack, severe infection, or a stroke

Signs and symptoms of lactic acidosis include: discomfort, muscle pain, difficult or fast breathing, extreme tiredness, weakness, upset stomach, stomach pain, feeling cold, low blood pressure or slow or irregular heartbeat.

If any of the above side effects occur, contact your doctor immediately.

INTERACTIONS WITH THIS MEDICATION

Always inform your doctor or pharmacist of all prescription over-the-counter, and herbal medicines that you are taking. Medicines which may require additional monitoring of your dose or condition include:
- other diabetes drugs, such as glyburide, insulin, and rosiglitazone
- medications that may increase blood sugar levels such as ‘water pills’ (diuretics), birth control pills, sympathomimetics (decongestants), thyroid medicines, prednisone (corticosteroid drugs), phenytoin, nicotinic acid, certain drugs which control high blood pressure (eg calcium channel blockers), and isoniazid
- furosemide
- nifedipine
- cationic drugs which may interfere with the elimination of metformin (eg. cimetidine, amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin)
- certain ‘blood thinners’ (coumarin-type anticoagulants)
- alcohol

Interactions with herbal products have not been established

PROPER USE OF THIS MEDICATION

Follow the directions provided by your doctor for using this medicine. Only take this medicine with food, and drink plenty of fluids while taking this medicine. Do not miss any doses. Swallow whole. Do not break or crush tablets.

Usual dose:
Initial dose is 1000 mg with evening meal. Maximum daily dose is 2000 mg.

Overdose:
If an overdose is suspected, contact your local poison control centre or emergency immediately. Symptoms of overdose may include rapid breathing or trouble in breathing, nausea and vomiting followed by diarrhea, drowsiness, weakness, dizziness, and headache.

Missed Dose:
If a dose of this medication has been missed it should be taken as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to the regular dosing schedule. Do not double doses.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Some common side effects include diarrhea, nausea and stomach upset. If they continue or are bothersome, check with your doctor.

After you are on the same dose for several days or weeks, if any of these symptoms come back, tell your doctor immediately. A late recurrence of stomach symptoms may be due to a serious medical condition (lactic acidosis).

This is not a complete list of side effects. For any unexpected effects while taking GLUMETZA and GLUMETZA (SB) contact your doctor or pharmacist.
**HOW TO STORE IT**

This medicine should be stored at room temperature (15-30°C). Keep out of reach of children.

**MORE INFORMATION**

This document plus the full product monograph, prepared for health professionals can be found at: http://webprod.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp or by contacting the sponsor:

Valeant Canada LP
4787 Levy St.,
Montreal, QC,
H4R 2P9
1-800-361-4261

This leaflet was prepared by Valeant Canada LP

Last revised: June 14, 2012

---

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
</tbody>
</table>

Lactic acidosis (a buildup of an acid in the blood) that can cause death or cardiovascular mortality

Symptoms include:
- very weak or tired
- unusual (not normal) muscle pain
- trouble breathing
- stomach pain with nausea and vomiting, or diarrhea
- feel cold, especially in arms and legs
- feel dizzy or lightheaded
- have a slow or irregular heartbeat

---

**REPORTING SUSPECTED SIDE EFFECTS**

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at: www.healthcanada.gc.ca/medeffect
- Call toll-free at: 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
    Health Canada
    Postal Locator 0701C
    Ottawa, ON K1A 0K9

Postal paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada website at: www.healthcanada.gc.ca/medeffect

*Note: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.*